

## **Central Nervous System (CNS) Biomarkers: Technologies and Global Markets**

Market Research Report | 2026-02-17 | 172 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$4650.00
- 2-5 Users License \$5580.00
- Site License \$6696.00
- Enterprise License \$8035.00

### **Report description:**

#### Description

#### Report Scope

The report examines and segments the global central nervous system (CNS) biomarkers market by disease, application, technology and biomarker type. It also provides insights into emerging trends and potential growth drivers. The report focuses on Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease and others. By application, it examines drug discovery and development, clinical diagnostics and personalized medicine. By technology, proteomics, molecular imaging and genomics are reviewed. Finally, biomarker types such as amyloid-beta, tau protein and others are considered.

The report also provides an inclusive regional analysis covering North America, Europe, Asia-Pacific, South America and the Middle East and Africa. It evaluates the impact of AI adoption on the CNS biomarkers industry and market dynamics, including drivers, challenges and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major market participants and their offerings.

Global revenue (\$ million) for the base year of 2024, estimates for 2025 and data for the forecast period 2025 through 2030 are also part of the report.

#### Report Includes

- 141 data tables and 44 additional tables
- An up-to-date overview and analysis of the global market for central nervous system (CNS) biomarkers
- In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of CAGRs through 2030
- Analysis of market opportunities with a holistic review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro-environmental factors prevailing in the market
- Explanation of market drivers, restraints and other forces impacting the global market
- Discussion of CNS disease segments, prevalence and gaps in treatment for Alzheimer's disease, depression, Parkinson's disease,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

multiple sclerosis, etc.

- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the practices of leading companies
- Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
- Profiles of the leading global companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott and Bio-Rad Laboratories Inc.

## Executive Summary

### Summary:

The global market for central nervous system (CNS) biomarkers is estimated to grow from \$7.6 billion in 2025 to reach \$13.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 through 2030.

CNS biomarkers are transforming drug development through high-level technologies in machine learning (ML), natural language processing (NLP) and predictive analytics. These support every part of the R&D process, from the identification of patients and protocol design to site selection and real-time trial monitoring. CNS biomarkers reduce operational inefficiencies by facilitating faster data-driven decisions, minimizing human error and shortening development timelines, which are all crucial in accelerating the development of cost-effective oncology therapies.

AI-powered electronic health records (EHR) and genomic and wearable device output analysis could lead to better stratification of patients, better prognosis and improved medication strategies. This approach is necessary for oncology due to the heterogeneity of lesions and the specificity of treatments.

### **Table of Contents:**

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Market Dynamics and Growth Factors

Emerging Technologies

Segmental Analysis

Regional Analysis

Conclusion

Chapter 2 Market Overview

Current Market Overview

Outlook

Analysis of Macroeconomic Factors

Impact of U.S. Tariffs on the Market

Impact of the Ukraine-Russia War

Global Economic Stability and Supply Chains

Public and Private R&D Investment

Healthcare Expenditure and Economic Growth

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Aging Population and Disease Burden  
Porter's Five Forces Analysis  
Bargaining Power of Buyers: Moderate to High  
Bargaining Power of Suppliers: High  
Potential for New Entrants: Moderate to Low  
Threat of Substitute: Moderate  
Competition in the Industry: High  
Chapter 3 Market Dynamics  
Market Dynamics Snapshot  
Market Drivers  
Prevalence of Neurological Disorders  
Advances in Diagnostic Technologies and Research  
Focus on Early Detection and Personalized Medicine  
Market Restraints  
High Cost of Advanced Diagnostic Assays  
Regulatory and Validation Challenges  
Limited Awareness and Adoption Among Healthcare Providers  
Market Opportunities  
Growth in Neurodegenerative Disease Research  
Expansion of Early Diagnosis and Screening Programs  
Integration with Personalized Medicine  
Chapter 4 Regulatory Landscape  
Regulatory Framework  
U.S.  
Europe  
India  
Australia  
Japan  
Chapter 5 Emerging Technologies and Patent Analysis  
Overview  
Emerging Technologies  
High-Resolution Mass Spectrometry  
Next-Generation Sequencing  
Multiplexed Immunoassays  
Single-Cell RNA Sequencing  
Patent Analysis  
Key Takeaways  
Patents by Year  
Patents by Leading Jurisdiction  
Patents by Applicants  
Chapter 6 Market Segmentation Analysis  
Segmentation Breakdown  
Global CNS Biomarkers Market, by Disease  
Key Takeaways  
Alzheimer's Disease  
MS, ALS and FTD  
Parkinson's Disease

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Others  
Global CNS Biomarkers Market, by Application  
Key Takeaways  
Drug Discovery and Development  
Clinical Diagnostics  
Personalized Medicine  
Global CNS Biomarkers Market, by Technology  
Key Takeaways  
Proteomics  
Molecular Imaging  
Genomics  
Global CNS Biomarkers Market, by Biomarker Type  
Key Takeaways  
Amyloid-Beta  
Tau Protein  
Others  
Geographic Breakdown  
Global CNS Biomarkers Market, by Region  
Key Takeaways  
North America  
Europe  
Asia-Pacific  
Middle East and Africa  
South America  
Chapter 7 Competitive Intelligence  
Industry Structure  
Company Market Share Analysis  
Strategic Analysis  
Chapter 8 Sustainability in the CNS Biomarkers Market: An ESG Perspective  
Introduction to ESG  
Sustainability Trends and Initiatives in the CNS Biomarkers Industry  
Concluding Remarks  
Chapter 9 Appendix  
Methodology  
Abbreviations  
Company Profiles  
ABBOTT  
BIOMERIEUX  
BIO-RAD LABORATORIES INC.  
C2N DIAGNOSTICS  
F. HOFFMANN-LA ROCHE LTD.  
FUJIREBIO  
LABCORP  
LILLY USA LLC.  
MERCK KGAA  
QUANTERIX  
QUEST DIAGNOSTICS INC.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

REVVITY  
SIEMENS HEALTHINEERS AG  
SYSMEX CORP.  
THERMO FISHER SCIENTIFIC INC.  
Emerging Start-ups/Market Disruptors

**Scotts International. EU Vat number: PL 6772247784**  
tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)  
[www.scotts-international.com](http://www.scotts-international.com)

**Central Nervous System (CNS) Biomarkers: Technologies and Global Markets**

Market Research Report | 2026-02-17 | 172 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4650.00
	2-5 Users License	\$5580.00
	Site License	\$6696.00
	Enterprise License	\$8035.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-08"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

